GlaxoSmithKline plc (NYSE:GSK) stock rose 2.17% (As on Feb 10, 11:32:14 AM UTC-4, Source: Google Finance) after the company beaten the earnings estimates for the fourth quarter of FY 21. The company now has a pipeline of 21 vaccines and 43 medicines, 22 of which are in pivotal studies. And this year GSK anticipates data readout from up to seven of the 11 new vaccines and medicines the company had identified as key future growth drivers. This includes the RSV vaccine for older adults in the first half of 2022 and several new potential specialty treatments, including those for rheumatoid arthritis, cancer and hepatitis B. 2022 sees the biggest change in GSKs recent corporate history with the creation of a new unique world leader dedicated to consumer in the middle of this year. This will be the culmination of a series of progressive strategic moves successfully executed over the last few years to build significant value and the new Consumer Healthcare Company. The company now in full countdown mode to demerger and by doing so, the aim is to unlock the potential of both GSK and Consumer Health, the strength in GSKs balance sheet and to maximize value for all the shareholders.

GSK in the fourth quarter of FY 21 has reported the adjusted earnings per share of 69 cents, beating the analysts’ estimates for the adjusted earnings per share of 63 cents. The company had reported the adjusted revenue growth of 3 percent to $12.84 billion in the fourth quarter of FY 21 driven by growth results from strong commercial execution behind our two-drug regimens and Dovato in particular. Sales of Dovato more than doubled to GBP787 million and are fast approaching 20% of the total HIV sales. Dolutegravir based regimens now hold the number one position in the share of the switch market across the US and Europe. Based on the strong momentum we believe Dovato is on track to deliver GBP1 billion of sales in 2022. Cabenuva is our first-in-class long-acting regimen for the treatment of HIV, for which the company received FDA approval last week for every two months dosing. The company ended 2021 on a high with the FDA approval of Apretude, the world’s first long-acting injectable for the prevention of HIV dosed every two months. Overall, in 2021, the company has generated GBP4.4 billion of free cash flow. Net cash generated from operations for the Group was GBP8 billion.